EXPERT OPINION FOR GUIDELINES FOR MANAGEMENT OF PATIENTS WITH COPD

  • Stanislav Šuškovič Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Mitja Košnik Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Matjaž Fležar Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Franc Šifrer Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Damjan Eržen Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Izidor Kern Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Robert Marčun Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Katarina Osolnik Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Viktorija Tomič Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Renato Eržen Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Jurij Šorli ml. Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik
  • Jurij Šorli Klinični oddelek za pljučne bolezni in alergijo Bolnišnica Golnik 4204 Golnik

Abstract

–

Downloads

Download data is not yet available.

References

National Heart, Lung, and Blood Institute. Morbidity & Mortality: Chartbook on cardiovascular, lung, and blood diseases. Bethesda: U. S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 1998. Available from: URL: http://www.nhlbi.nih.gov/nhlbi/seiin/ other/cht-book/htm.

Georgopoluas D, Anthonisen NR. Symptoms and signs of COPD. In: Cherniak NS ed. Chronic obstructive pulmonary disease. Toronto: WB Saunders Co., 1991: 357–63.

World Health Organization, Geneva. World Health Report. 2000. Available from URL: http://www.who.int/whr/2000/en/statistics.htm.

The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. A clinical practice guideline for treating tobacco use and dependence. JAMA 2000; 28: 3244–54.

American Medical Association. Guidelines for the diagnosis and treatment of nicotine dependence: How to help patients stop smoking. Washington: American Medical Association, 1994.

Glynn TJ, Manley MW, Pechacek TF. Physician-initiated smoking cessation program: the National Cancer Institute trials. Prog Clin Biol Res 1990; 339: 11–25.

Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 2000; 321: 355–8.

The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52: Suppl 5: S1–28.

Samet J, Utell MJ. Ambient air pollution. In: Rosenstock L, Cullen M eds. Textbook of occupational and environmental medicine. Philadelphia: WB Saunders, 1994: 53–60.

Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122: 823–32.

Niewoehner DE. Anatomic and pathophysiological correlations in COPD. In: Baum GL, Crapo JD, Celli BR, Karlinsky JB eds. Textbook of pulmonary diseases. Philadelphia: Lippincott-Raven, 1998: 823–42.

Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160: 893–8.

Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530–4.

Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, Donner CF. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12: 380–6.

Yamamoto C, Yoneda T, Yoshikawa M, Fu A, Tokuyama T, Tsukaguchi K, Narita N. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505–10.

Mueller R, Chanez P, Campbell AM, Bousquet J, Heusser C, Bullock GR. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 1996; 90: 79–85.

Wright JL, Lawson LM, Pare PD, Wiggs BJ, Kennedy S, Hogg JC. Morphology of peripheral airways in current smokers and ex-smokers. Am Rev Respir Dis 1983; 127: 474–7.

Wilson R. The role of infection in COPD. Chest 1998; 113: 242S–8S.

Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–45.

Soler N, Torres A, Ewig S, Gonzales J, Celis R, El-Ebiary M et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498–505.

Smith CB, Kanner RE, Golden CA, Klauber MR, Renzetti AD Jr. Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases. J Infect Dis 1980; 141: 271–80.

Anderson HR, Spix C, Medina S, Schouten JP et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997; 10: 1064–71.

The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52: Suppl 5: S1–28.

American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Crit Care Med 1995; 152: S77–121.

Siafakis NM, Vermiere P, Pride NB, Paoletti P, Gibson J, Howard P et al. Optimal assessment and management of chronic obstructive pulmonary disease. The European Respiratory Society Task Force 1995; 8: 1398–420.

Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, Simonneau G, Benito S, Gasparetto A, Lemaire F. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817–22.

Kramer N, Meyer TJ, Meharg J, Cece RD, Hill NS. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151: 1799–806.

Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000; 355: 1931–5.

Esteban A, Anzueto A, Alia I, Gordo F et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med 2000; 161: 1450–8.

Esteban A, Frutos F, Tobin MJ, Alia I et al. for the Spanish Lung Failure Collaborative Group. A comparison of four methods of weaning patients from mechanical ventilation. N Engl J Med 1995; 332: 345–50.

Brochard L, Rauss A, Benito S, Conti G, Mancebo J, Rekik N, Gasparetto A, Lemaire F. Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation. Am J Respir Crit Care Med 1994; 150; 896–903.

Emerman CL, Connors AF, Lukens TW, Effron D, May ME. Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1989; 18: 523–7.

Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407–12.

Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456–60.

Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941–7.

Higgins BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991; 4: 415–20.

Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest 1987; 91: 804–7.

Ikeda A, Nishimura K, Koyama H, Tsukino M, Mishima M, Izumi T. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 48–53.

Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, Newhouse MT. Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069–74.

Thompson WH, Nielson CP, Carvalho P. Controlled trial of oral prednisone in out-patients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407–12.

Davies L, Angus RM, Carverley PM. Oral corticosteroids in patients admitted to hospital with exacerbation of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456–60.

Niewoehner DE, Erbland ML, Deupree RH. Effect of systemic glucocorticoids on exacerbations of chronic pulmonary disease. N Engl J Med 1999; 340: 1941–7.

Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948–53.

Vestbo J, Sorensen T, Lange P et al. Long-term effects of inhaled budesonide in mild and moderate chronic obstructive lung disease: a randomised controlled trial. Lancet 1999; 353: 1819–23.

Burge PS, Carverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE TRIAL. BMJ 2000; 320: 1297–303.

Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: A three-center study. Am Rev Respir Dis 1989; 139: 1188–91.

Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988; 297: 1506–10.

Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995; 50: 750–4.

Taylor DR, Buick B, Kinney C, Lowry RC, McDevitt DG. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 1985; 131: 747–51.

Van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878–85.

COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994; 105: 1411–9.

Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521–5.

O’Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MC, Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992; 86: 317–25.

Tashkin DP, Bleecker E, Braun S, Campbell S, DeGraff AC Jr., Hudgel DW, Boyars MC, Sahn S. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med 1996; 100: 62S–9S.

Senderovitz T, Vestbo J, Frandsen J, Maltbaek N, Norgaard M, Nielsen C, Kampmann JP. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med 1999; 93: 715–8.

Nichol KL, Margolis KL, Wuorenma J. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778–84.

Williams JH Jr., Moser KM. Pneumococcal vaccine and patients with chronic lung disease. Ann Intern Med 1986; 104: 106–9.

American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–121.

Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315: 1318–27.

Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000; 2:

British Thoracic Society research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airway obstruction. Thorax 1985; 40: 832–5.

Irwin RS, Boulet LP, Cloutier MM. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998; 114: 133S–8S.

Bardsley PA, Howard P, DeBacker W, Vermeire P et al. Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease. Eur Respir J 1991; 4: 308–10.

Winkelmann BR, Kullmer TH, Kneissl DG. Low dose almytrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. Chest 1994; 105: 1383–91.

Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362–8.

Goldstein RS, Gort EH, Stubbing D, Avendano MA, Guyatt GH. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344: 1394–7.

Wijkstra PJ, Van Altena R, Kraan J, Otten V, Postma DS, Koeter GH. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J 1994; 7: 269–73.

McGavin CR, Gupta SP, Lloyd EL, McHardy GJ. Physical rehabilitation for the chronic bronchitis: results of a controlled trial of exercises in the home. Thorax 1977; 32; 307–11.

Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391–8.

Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681–6.

Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995; 333: 710–14.

How to Cite
1.
Šuškovič S, Košnik M, Fležar M, Šifrer F, Eržen D, Kern I, Marčun R, Osolnik K, Tomič V, Eržen R, Šorli ml. J, Šorli J. EXPERT OPINION FOR GUIDELINES FOR MANAGEMENT OF PATIENTS WITH COPD. TEST ZdravVestn [Internet]. 1 [cited 5Aug.2024];71(11). Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/1654
Issue
Vol 71 No 11 (2002): November
Section
Quality and safety


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence. 

Most read articles by the same author(s)